Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation

Journal of Cellular Biochemistry

Volumn 111, Issue 6, 2010, Pages 1546-1555

  Liu, Youhong ^a   Hock, Janet M ^a   Sullivan, Con ^a   Fang, Geying ^a   Cox, Allison J ^a   Davis, Kathleen T ^b   Davis, Bruce H ^b   Li, Xiong ^a  

^a Maine Institute for Human Genetics & Health   (United States)

^b Trillium Diagnostics   (United States)

Author keywords

arsenite; cell cycle; cell proliferation; DNA replication; protein stabilization; signal transduction

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ARSENIC TRIOXIDE; CELL CYCLE PROTEIN 6; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LOW DRUG DOSE; PRIORITY JOURNAL; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ARSENICALS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; FLOW CYTOMETRY; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NUCLEAR PROTEINS; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES;

EID: 78649781549     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22886     Document Type: Article

References (50)

1. Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E,. 2002. Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res Treat 73: 61-73.
2. Benbrahim-Tallaa L, Webber MM, Waalkes MP,. 2005. Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. Environ Health Perspect 113: 1134-1139.
3. Benbrahim-Tallaa L, Webber MM, Waalkes MP,. 2007. Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ Health Perspect 115: 243-247.
4. Borlado LR, Mendez J,. 2008. CDC6: From DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis 29: 237-243.
5. Bornhauser BC, Bonapace L, Lindholm D, Martinez R, Cario G, Schrappe M, Niggli FK, Schafer BW, Bourquin JP,. 2007. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 110: 2084-2091.
6. Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP,. 2001. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 175: 260-268.
7. Cohen SM, Ellwein LB,. 1990. Cell proliferation in carcinogenesis. Science 249: 1007-1011.
8. Dong Z,. 2002. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect 110 (Suppl 5): 757-759. (Pubitemid 35276862)
9. DuMond JW, Jr., Singh KP,. 2007. Gene expression changes and induction of cell proliferation by chronic exposure to arsenic of mouse testicular Leydig cells. J Toxicol Environ Health A 70: 1150-1154.
10. El Mchichi B, Hadji A, Vazquez A, Leca G,. 2007. p38 MAPK and MSK1 mediate caspase-8 activation in manganese-induced mitochondria-dependent cell death. Cell Death Differ 14: 1826-1836.
11. Fong LY, Li JX, Farber JL, Magee PN,. 1996. Cell proliferation and esophageal carcinogenesis in the zinc-deficient rat. Carcinogenesis 17: 1841-1848.
12. Hateboer G, Wobst A, Petersen BO, Le Cam L, Vigo E, Sardet C, Helin K,. 1998. Cell cycle-regulated expression of mammalian CDC6 is dependent on E2F. Mol Cell Biol 18: 6679-6697.
13. Huang C, Ma WY, Li J, Dong Z,. 1999a. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res 59: 3053-3058.
14. Huang C, Ma WY, Li J, Goranson A, Dong Z,. 1999b. Requirement of ERK, but not JNK, for arsenite-induced cell transformation. J Biol Chem 274: 14595-14601.
15. Huang Y, Zhang J, McHenry KT, Kim MM, Zeng W, Lopez-Pajares V, Dibble CC, Mizgerd JP, Yuan ZM,. 2008. Induction of cytoplasmic accumulation of p53: A mechanism for low levels of arsenic exposure to predispose cells for malignant transformation. Cancer Res 68: 9131-9136.
16. Huff J, Chan P, Nyska A,. 2000. Is the human carcinogen arsenic carcinogenic to laboratory animals? Toxicol Sci 55: 17-23.
17. Hwang BJ, Utti C, Steinberg M,. 2006. Induction of cyclin D1 by submicromolar concentrations of arsenite in human epidermal keratinocytes. Toxicol Appl Pharmacol 217: 161-167.
18. Jensen TJ, Novak P, Eblin KE, Gandolfi AJ, Futscher BW,. 2008. Epigenetic remodeling during arsenical-induced malignant transformation. Carcinogenesis 29: 1500-1508.
19. Johnson DG, Walker CL,. 1999. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39: 295-312.
20. Kachinskas DJ, Phillips MA, Qin Q, Stokes JD, Rice RH,. 1994. Arsenate perturbation of human keratinocyte differentiation. Cell Growth Differ 5: 1235-1241.
21. Kang YH, Lee SJ,. 2008. The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol 217: 23-33.
22. Karakaidos P, Taraviras S, Vassiliou LV, Zacharatos P, Kastrinakis NG, Kougiou D, Kouloukoussa M, Nishitani H, Papavassiliou AG, Lygerou Z, Gorgoulis VG,. 2004. Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: Synergistic effect with mutant p53 on tumor growth and chromosomal instability-Evidence of E2F-1 transcriptional control over hCdt1. Am J Pathol 165: 1351-1365.
23. Lau AT, Li M, Xie R, He QY, Chiu JF,. 2004. Opposed arsenite-induced signaling pathways promote cell proliferation or apoptosis in cultured lung cells. Carcinogenesis 25: 21-28.
24. Lu T, Liu J, LeCluyse EL, Zhou YS, Cheng ML, Waalkes MP,. 2001. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci 59: 185-192.
25. Luo F, Yee JK, Huang SH, Wu LT, Jong AY,. 2006. Downregulation of human Cdc6 protein using a lentivirus RNA interference expression vector. Methods Mol Biol 342: 287-293.
26. Luster MI, Simeonova PP,. 2004. Arsenic and urinary bladder cell proliferation. Toxicol Appl Pharmacol 198: 419-423.
27. Melnick RL, Huff J, Barrett JC, Maronpot RR, Lucier G, Portier CJ,. 1993. Cell proliferation and chemical carcinogenesis: Symposium overview. Environ Health Perspect 101 (Suppl 5): 3-7. (Pubitemid 24096318)
28. Ohta S, Koide M, Tokuyama T, Yokota N, Nishizawa S, Namba H,. 2001. Cdc6 expression as a marker of proliferative activity in brain tumors. Oncol Rep 8: 1063-1066.
29. Ouyang W, Li J, Ma Q, Huang C,. 2006. Essential roles of PI-3K/Akt/IKKbeta/NFkappaB pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis 27: 864-873.
30. Ouyang W, Li J, Zhang D, Jiang BH, Huang DC,. 2007. PI-3K/Akt signal pathway plays a crucial role in arsenite-induced cell proliferation of human keratinocytes through induction of cyclin D1. J Cell Biochem 101: 969-978.
31. Page K, Li J, Hershenson MB,. 2001. p38 MAP kinase negatively regulates cyclin D1 expression in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 280: L955-L964.
32. Pinyol M, Salaverria I, Bea S, Fernandez V, Colomo L, Campo E, Jares P,. 2006. Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability. Int J Cancer 119: 2768-2774.
33. Platanias LC,. 2009. Biological responses to arsenic compounds. J Biol Chem 284: 18583-18587.
34. Prindull G,. 2008. Final checkup of neoplastic DNA replication: Evidence for failure in decision-making at the mitotic cell cycle checkpoint G(1)/S. Exp Hematol 36: 1403-1416.
35. Salnikow K, Cohen MD,. 2002. Backing into cancer: Effects of arsenic on cell differentiation. Toxicol Sci 65: 161-163.
36. Sanchez Y, Calle C, de Blas E, Aller P,. 2009. Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases. Chem Biol Interact 182: 37-44.
37. Schoen A, Beck B, Sharma R, Dube E,. 2004. Arsenic toxicity at low doses: Epidemiological and mode of action considerations. Toxicol Appl Pharmacol 198: 253-267.
38. Shen J, Liu J, Xie Y, Diwan BA, Waalkes MP,. 2007. Fetal onset of aberrant gene expression relevant to pulmonary carcinogenesis in lung adenocarcinoma development induced by in utero arsenic exposure. Toxicol Sci 95: 313-320.
39. Sherr CJ,. 2000. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res 60: 3689-3695.
40. Shibata T, Solo-Gabriele HM, Fleming LE, Cai Y, Townsend TG,. 2007. A mass balance approach for evaluating leachable arsenic and chromium from an in-service CCA-treated wood structure. Sci Total Environ 372: 624-635.
41. Simeonova PP, Wang S, Toriuma W, Kommineni V, Matheson J, Unimye N, Kayama F, Harki D, Ding M, Vallyathan V, Luster MI,. 2000. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: Association with activating protein-1 transactivation. Cancer Res 60: 3445-3453.
42. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, Wood R, Kosnett MJ, Smith MT,. 1992. Cancer risks from arsenic in drinking water. Environ Health Perspect 97: 259-267.
43. Snow ET, Sykora P, Durham TR, Klein CB,. 2005. Arsenic, mode of action at biologically plausible low doses: What are the implications for low dose cancer risk? Toxicol Appl Pharmacol 207: 557-564.
44. Tashiro E, Tsuchiya A, Imoto M,. 2007. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 98: 629-635.
45. Trouba KJ, Wauson EM, Vorce RL,. 2000a. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol Appl Pharmacol 164: 161-170.
46. Trouba KJ, Wauson EM, Vorce RL,. 2009b. Sodium arsenite inhibits terminal differentiation of murine C3H 10T1/2 preadipocytes. Toxicol Appl Pharmacol 168: 25-35.
47. Wagner EF, Nebreda AR,. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
48. Yan Z, DeGregori J, Shohet R, Leone G, Stillman B, Nevins JR, Williams RS,. 1998. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA 95: 3603-3608.
49. Ye J, Li A, Liu Q, Wang X, Zhou J,. 2005. Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells. Clin Exp Pharmacol Physiol 32: 1042-1048.
50. Zhang D, Li J, Gao J, Huang C,. 2009. c-Jun/AP-1 pathway-mediated cyclin D1 expression participates in low dose arsenite-induced transformation in mouse epidermal JB6 Cl41 cells. Toxicol Appl Pharmacol 235: 18-24.